Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

• Thijs W.H. Flinsenberg,
• Charnelle C. Tromedjo,
• Nan Hu,
• Ye Liu,
• Yin Guo,
• Kevin Y.T. Thia,
• Tahereh Noori,
• Xiaomin Song,
• Han X. Aw Yeang,
• Daniela G. Tantalo,
• Sasanka Handunnetti,
• John F. Seymour,
• Andrew W. Roberts,
• David Ritchie,
• Rachel Koldej,
• Paul J. Neeson,
• Lai Wang,
• Joseph A. Trapani,
• Constantine S. Tam,
• Ilia Voskoboinik

Affiliations

Thijs W.H. Flinsenberg

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Charnelle C. Tromedjo

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Nan Hu

BeiGene LTD, Beijing, China

Ye Liu

BeiGene LTD, Beijing, China

Yin Guo

BeiGene LTD, Beijing, China

Kevin Y.T. Thia

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Tahereh Noori

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Xiaomin Song

BeiGene LTD, Beijing, China

Han X. Aw Yeang

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia

Daniela G. Tantalo

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Sasanka Handunnetti

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia

John F. Seymour

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia

Andrew W. Roberts

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia

David Ritchie

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia;The ACRF Translational Research Laboratory; Royal Melbourne Hospital, Parkville, Victoria, Australia

Rachel Koldej

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;The ACRF Translational Research Laboratory; Royal Melbourne Hospital, Parkville, Victoria, Australia

Paul J. Neeson

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia

Lai Wang

BeiGene LTD, Beijing, China

Joseph A. Trapani

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia

Constantine S. Tam

Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia;Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia

Ilia Voskoboinik

Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia